GSK’s (GSK) “Hold” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday,Digital Look reports. They currently have a GBX 1,900 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential downside of 1.70% from the company’s current price.

A number of other analysts have also recently commented on GSK. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research report on Thursday, March 26th. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a research report on Tuesday, April 14th. Finally, Citigroup lowered their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of GBX 2,034.29.

GSK Stock Performance

GSK stock opened at GBX 1,932.91 on Wednesday. The business’s fifty day moving average is GBX 2,006.72 and its 200-day moving average is GBX 1,949.60. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The company has a market cap of £77.16 billion, a P/E ratio of 13.60, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. GSK has a twelve month low of GBX 1,288.61 and a twelve month high of GBX 2,282.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 EPS for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The business had revenue of GBX 762.90 billion during the quarter. Equities research analysts forecast that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In other news, insider Anne Beal bought 196 shares of the stock in a transaction on Friday, March 20th. The shares were acquired at an average cost of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Wendy Becker bought 4,000 shares of the stock in a transaction on Wednesday, April 29th. The stock was purchased at an average price of GBX 1,963 per share, for a total transaction of £78,520. Insiders have bought 9,619 shares of company stock worth $19,452,794 in the last three months. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.